CLINICAL_TRIALS
trial_result
· 2009-11-26
Clinical Trial Update: Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17 [Phase 3]
Summary
Phase 3 study evaluating SPD503 for ADHD in children 6-17 has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Shire | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 3 | Status: COMPLETED | Results posted: 2009-11-26